Alpha-Synuclein Pathophysiology in Neurodegenerative Disorders: A Review Focusing on Molecular Mechanisms and Treatment Advances in Parkinson’S Disease Can we halt Parkinson’s? Review finds α-syn therapies like immunotherapy may slow NDD progression. #ParkinsonsDisease #Synucleinopathies

Can we halt Parkinson’s? Review finds α-syn therapies like immunotherapy may slow NDD progression. #ParkinsonsDisease #Synucleinopathies
www.rimpacts.com/rd/p?c=10069... 📄DOI: doi.org/10.1007/s105...

Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review - Molecular Neurodegeneration Molecular Neurodegeneration - Alpha-synucleinopathies are common disorders that are expected to become increasingly prevalent in the future along with the longer life expectancy. However, their...

Diagnostic #biomarkers for α- #synucleinopathies- state of the art and future developments: a systematic review

V. Donadio, M. Ingelsson...S. Pritzkow @unibo.it

link.springer.com/article/10.1...

Targeted α-Synuclein mRNA Degradation by PMO-Based RNA-Degrading Chimeras α-Synucleinopathies are devastating neurodegenerative diseases characterized by pathological accumulation of a neuronal protein, α-synuclein (αSyn). Lowering soluble αSyn levels is a promising therape...

New @bioRxiv: We built PMO-based RNA-degrading chimeras (RDCs) to degrade SNCA mRNA & lower α-synuclein.

This approach prevents prion-like seeding & protects neurons in cellular & *in vivo* models.

A promising new therapy for #synucleinopathies.
doi.org/10.1101/2025...

✅ Our "Emerging Insights into #LewyBodyDisease" review series is now complete!

Dive into the full collection covering diagnosis, management & mechanisms of LBD

Explore all articles here ➡️ biomedcentral.com/collections/...

#synucleinopathies #Parkinsons #microbiome #neuroimaging #sleep

Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review - Molecular Neurodegeneration Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), is characterized by cognitive decline, sleep disturbances, motor dysfunction, and other...

'Alpha-synuclein seeding amplification assays in #Lewybodydementia: a brief review'

Maria Bregendahl, Zeynep Bengisu Kaya, Wolfgang Singer, Pamela J. McLean @mayoclinic.org #synucleinopathies #biomarker

molecularneurodegeneration.biomedcentral.com/articles/10....

Skin test detects evidence of Parkinson’s and related disorders A study showed that a simple skin biopsy could identify people who had Parkinson’s disease or similar disorders with a high degree of accuracy.

A study showed that a simple #skinbiopsy could identify people who had PD or similar disorders with a high degree of accuracy.
The findings could lead to earlier, more accurate diagnosis of the neurodegenerative cond ~ #synucleinopathies
www.nih.gov/news-events/...

www.medrxiv.org/content/10.1...

#Medsky🧪 #neurosky #neuroimmunology #immunosky #publichealth A high proportion of individuals affected by iRBD eventually develop synuclein-specific neurodegenerative disorders (i.e., #synucleinopathies) such as PD, DLB or MSA

Toward a biological definition of neuronal and glial synucleinopathies - Nature Medicine Parkinson’s diseases and other synucleinopathies are on the verge of a major paradigm shift toward being defined and staged by their biology, rather than symptoms; this Perspective offers context on p...

#Medsky🧪 #

#Parkinsonsdisease and other #synucleinopathies are undergoing a paradigm shift towards being defined and staged by biology, rather than symptoms @natmedicine.bsky.social

www.nature.com/articles/s41...

www.nature.com/articles/s41...